Literature DB >> 25234946

Unmet clinical need in autoimmune liver diseases.

Jessica K Dyson1, Gwilym Webb2, Gideon M Hirschfield3, Ansgar Lohse4, Ulrich Beuers5, Keith Lindor6, David E J Jones7.   

Abstract

Despite recent advances in understanding and treatment, there remain significant areas of unmet clinical need in each of the autoimmune liver diseases (AILDs). The evolving research landscape and emerging large patient cohorts are creating unique opportunities to translate science into new therapies and care pathways, with the potential to significantly improve the lives of AILD patients. However, the areas of unmet need represent real challenges, which need to be addressed, if this vision is to be realised. This review describes the areas of unmet need in AILD in adults relating to diagnostic and prognostic assessment, primary therapy, symptom management, trial design and delivery, and structured care delivery, with the aim of focusing future research prioritisation.
Copyright © 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autoimmune hepatitis; Autoimmune liver diseases; IgG4 disease; Primary biliary cirrhosis; Primary sclerosing cholangitis; Stratified care delivery; Unmet clinical need

Mesh:

Year:  2014        PMID: 25234946     DOI: 10.1016/j.jhep.2014.09.010

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  19 in total

1.  18F-FAC PET Selectively Images Liver-Infiltrating CD4 and CD8 T Cells in a Mouse Model of Autoimmune Hepatitis.

Authors:  Jessica R Salas; Bao Ying Chen; Alicia Wong; Donghui Cheng; John S Van Arnam; Owen N Witte; Peter M Clark
Journal:  J Nucl Med       Date:  2018-04-26       Impact factor: 10.057

Review 2.  Novel therapeutic targets in primary biliary cirrhosis.

Authors:  Jessica K Dyson; Gideon M Hirschfield; David H Adams; Ulrich Beuers; Derek A Mann; Keith D Lindor; David E J Jones
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-02-03       Impact factor: 46.802

3.  The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.

Authors:  Gideon M Hirschfield; Jessica K Dyson; Graeme J M Alexander; Michael H Chapman; Jane Collier; Stefan Hübscher; Imran Patanwala; Stephen P Pereira; Collette Thain; Douglas Thorburn; Dina Tiniakos; Martine Walmsley; George Webster; David E J Jones
Journal:  Gut       Date:  2018-03-28       Impact factor: 23.059

Review 4.  Primary sclerosing cholangitis and the management of uncertainty and complexity.

Authors:  Katherine Arndtz; Gideon M Hirschfield
Journal:  Frontline Gastroenterol       Date:  2017-07-25

5.  Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis: Predictors of Gamma Glutamyltransferase Normalization and Favorable Clinical Course.

Authors:  Mark Deneau; Emily Perito; Amanda Ricciuto; Nitika Gupta; Binita M Kamath; Sirish Palle; Bernadette Vitola; Vratislav Smolka; Federica Ferrari; Achiya Z Amir; Tamir Miloh; Alexandra Papadopoulou; Parvathi Mohan; Cara Mack; Kaija-Leena Kolho; Raffaele Iorio; Wael El-Matary; Veena Venkat; Albert Chan; Lawrence Saubermann; Pamela L Valentino; Uzma Shah; Alexander Miethke; Henry Lin; M K Jensen
Journal:  J Pediatr       Date:  2019-03-14       Impact factor: 4.406

6.  May Previous Hepatitis B Virus Infection Be Involved in Etiology and Pathogenesis of Autoimmune Liver Diseases?

Authors:  Sergey Batskikh; Sergey Morozov; Elena Vinnitskaya; Evgeniya Sbikina; Zanna Borunova; Alexey Dorofeev; Yulia Sandler; Kirill Saliev; Dmitry Kostyushev; Sergey Brezgin; Anastasiya Kostyusheva; Vladimir Chulanov
Journal:  Adv Ther       Date:  2021-11-11       Impact factor: 3.845

Review 7.  The intestinal and biliary microbiome in autoimmune liver disease-current evidence and concepts.

Authors:  Timur Liwinski; Melina Heinemann; Christoph Schramm
Journal:  Semin Immunopathol       Date:  2022-05-10       Impact factor: 11.759

8.  The Natural History and Prognosis of Primary Biliary Cirrhosis with Clinical Features of Autoimmune Hepatitis.

Authors:  Fan Yang; Qixia Wang; Zhaoyue Wang; Qi Miao; Xiao Xiao; Ruqi Tang; Xiaoyu Chen; Zhaolian Bian; Haiyan Zhang; Yue Yang; Li Sheng; Jingyuan Fang; Dekai Qiu; Edward L Krawitt; M Eric Gershwin; Xiong Ma
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

9.  Autoantibody Profile of Adult Patients With Childhood Onset Type 2 Autoimmune Hepatitis.

Authors:  Marek Woynarowski; Małgorzata Woźniak; Bożena Cukrowska; Aldona Wierzbicka; Simon D Lytton
Journal:  J Clin Lab Anal       Date:  2015-12-17       Impact factor: 2.352

10.  Protective effects of astaxanthin on ConA-induced autoimmune hepatitis by the JNK/p-JNK pathway-mediated inhibition of autophagy and apoptosis.

Authors:  Jingjing Li; Yujing Xia; Tong Liu; Junshan Wang; Weiqi Dai; Fan Wang; Yuanyuan Zheng; Kan Chen; Sainan Li; Huerxidan Abudumijiti; Zheng Zhou; Jianrong Wang; Wenxia Lu; Rong Zhu; Jing Yang; Huawei Zhang; Qin Yin; Chengfen Wang; Yuqing Zhou; Jie Lu; Yingqun Zhou; Chuanyong Guo
Journal:  PLoS One       Date:  2015-03-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.